Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midapril hydrochloride plus hydrochlorothiazide for essential hypertension
ChiCTR2400089563Phase 4Not yet recruiting
- Sponsor
- Jiangyou Second People's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of imidapril in essential hypertension (2 arms), sponsored by Jiangyou Second People's Hospital. Primary endpoint: Antihypertensive efficiency. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
imidapril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2400089563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089563.